On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

WUHAN, China I, 2025 I Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address ...

Hanx Biopharmaceuticals chairman Dr Faming Zhang said: "We are thrilled to see the first patient entered into a clinical ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success ...

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...

Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...

The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...